Markets

Market

News Details

(25/05/2026 15:30)

Fredun Pharma. Q4 net profit jumps 56.58% at Rs 11.07 cr

The company reported standalone net profit of Rs 11.07 crore for the quarter ended March 31, 2026 as compared to Rs 7.07 crore in the same period last year, registering a year-on-year growth of 56.58 per cent.

Net revenue of the company rose substantially by 27.18 per cent at Rs 210.41 crore in January-March quarter of this fiscal as against Rs 165.44 crore in the corresponding period last year.

During January-March quarter, operating expenses increased by 22.64 per cent to Rs 183.92 crore from Rs 149.97 crore in year ago period.

Other Income grew by 34.01 per cent at Rs 2.64 crore versus (Mar'25 Rs 1.97 crore).

Operating Profit surged by 71.23 per cent to Rs 26.49 crore as against Rs 15.47 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 34.65 per cent in March quarter.

Interest grew by 77.79 per cent y-o-y to Rs 14.49 crore, while Taxation decreased by 51.55 per cent at Rs 0.47 crore (Mar'25 Rs 0.97 crore).

Prevent Unauthorized Transactions in your demat account -> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL on the same day....................issued in the interest of investors.
KYC is one-time exercise while dealing in securities markets -> Once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.